About event
Acute myeloid leukemia is the most frequent leukemia worldwide with very limited therapeutic options. For decades, the therapy was relying mainly on chemotherapy, while only recently the first targeted agent venetoclax was approved. Although this meant a major breakthrough in AML therapy, two thirds of patients do not benefit from venetoclax treatment in a long-term. The mechanisms responsible for venetoclax failure are largely unknown and, more importantly, there are no alternative therapies available for the resistant patients. To understand the resistance mechanisms, we have generated venetoclax-resistant cell lines and subjected them to the genome-wide CRISPR/Cas9 knockout screening. Thereby we aim to reveal genes responsible for venetoclax unresponsiveness. We have also analyzed changes in the transcriptome profiles in the resistant AML cells by quantitative PCR, RNA sequencing or single-cell RNA sequencing. Finally, we have been screening a library of approved drugs on patient´s cells in order to identify their unique vulnerabilities and to potentially propose alternative treatments for the unresponsive patients.
More information
This event is part of the Principal Investigator Seminar Series, the schedule of seminars can be found here.
